INT193251

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2006
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 13
Total Number 15
Disease Relevance 8.32
Pain Relevance 2.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CYSLTR1) signal transducer activity (CYSLTR1)
Anatomy Link Frequency
eosinophils 2
leukocytes 1
CYSLTR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
long-term potentiation 78 100.00 Very High Very High Very High
depression 72 100.00 Very High Very High Very High
Inflammation 126 99.84 Very High Very High Very High
antagonist 65 99.36 Very High Very High Very High
aspirin 161 97.54 Very High Very High Very High
Spinal cord 10 93.48 High High
cINOD 13 70.96 Quite High
Pain 8 65.88 Quite High
agonist 69 65.60 Quite High
chemokine 18 63.56 Quite High
Disease Link Frequency Relevance Heat
Depression 72 100.00 Very High Very High Very High
INFLAMMATION 162 99.84 Very High Very High Very High
Asthma 169 99.76 Very High Very High Very High
Chronic Sinusitis 74 97.38 Very High Very High Very High
Urticaria 60 96.64 Very High Very High Very High
Rhinitis 54 93.84 High High
Frailty 10 93.76 High High
Edema 8 92.76 High High
Cv Unclassified Under Development 10 91.44 High High
Targeted Disruption 15 91.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As shown in Figure 7D, [3H]-LTD4 bound to HEK293 membranes harbouring CysLT2 and was dose-dependently displaced by unlabelled LTD4 with an IC50 of 10.3 nM.
LTD4 Binding (bound) of
1) Confidence 0.32 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2839267 Disease Relevance 0 Pain Relevance 0
In conclusion, these results align well with the observation that LTD4 neither activates nor binds to GPR17.
LTD4 Binding (binds) of
2) Confidence 0.32 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2839267 Disease Relevance 0 Pain Relevance 0.03
Of interest, a recent study performed in patients with chronic rhinosinusitis/aspirin intolerance showed that effects of cysteinyl leukotrienes in the nasal mucosa of these patients seems to occur mainly via interaction with CysLT1 on inflammatory leukocytes.
CysLT1 Binding (interaction) of in leukocytes associated with aspirin, inflammation and chronic sinusitis
3) Confidence 0.28 Published 2006 Journal Respir Res Section Body Doc Link PMC1481584 Disease Relevance 0.94 Pain Relevance 0.29
Very recently, GPR17 was shown to function as a negative regulator of CysLT1 receptor activation in stable cell lines by inhibiting LTD4 binding to CysLT1.
CysLT1 Binding (binding) of
4) Confidence 0.25 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2839267 Disease Relevance 0.44 Pain Relevance 0.08
Very recently, GPR17 was shown to function as a negative regulator of CysLT1 receptor activation in stable cell lines by inhibiting LTD4 binding to CysLT1.
LTD4 Binding (binding) of
5) Confidence 0.24 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2839267 Disease Relevance 0.44 Pain Relevance 0.08
Given these results, we decided to carry out homologous competition binding to assess whether LTD4 binds to hGPR17-L and -S.
LTD4 Spec (whether) Binding (binds) of
6) Confidence 0.24 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2839267 Disease Relevance 0 Pain Relevance 0
protein concentrations (CysLT1: rho = 0,574, p = 0.01; CysLT2: rho = 0,523; p < 0.05), ECP (CysLT1: rho = 0,544, p = 0.02; CysLT2: rho = 0,413; p = 0.03) and the total number of activated eosinophils (CysLT1: rho = 0,546, p = 0.02; CysLT2: rho = 0,614; p = 0.03).
CysLT1 Binding (0.03) of in eosinophils
7) Confidence 0.22 Published 2006 Journal Respir Res Section Body Doc Link PMC1481584 Disease Relevance 0.47 Pain Relevance 0.12
protein concentrations (CysLT1: rho = 0,574, p = 0.01; CysLT2: rho = 0,523; p < 0.05), ECP (CysLT1: rho = 0,544, p = 0.02; CysLT2: rho = 0,413; p = 0.03) and the total number of activated eosinophils (CysLT1: rho = 0,546, p = 0.02; CysLT2: rho = 0,614; p = 0.03).
CysLT1 Binding (0.03) of in eosinophils
8) Confidence 0.22 Published 2006 Journal Respir Res Section Body Doc Link PMC1481584 Disease Relevance 0.60 Pain Relevance 0.18
Montelukast, Zafirlukast and Pranlukast [13] are LT receptor antagonists that demonstrate high-affinity binding to the CysLT1 receptor.

2.

CysLT1 receptor Binding (binding) of associated with antagonist
9) Confidence 0.16 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2945673 Disease Relevance 0.95 Pain Relevance 0.21
In addition, three promoter polymorphisms in the cysteinyl leukotriene receptor 1 gene were associated with AIA in males [46].
cysteinyl leukotriene receptor 1 gene Binding (associated) of associated with asthma
10) Confidence 0.15 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2972220 Disease Relevance 1.33 Pain Relevance 0.19
CysLT2 binds both LTC4 and LTD4 with an affinity of approximately 10 nM, and both receptors bind LTE4 with affinities near 100 nM [24].
LTD4 Binding (binds) of
11) Confidence 0.11 Published 2010 Journal PLoS Biology Section Body Doc Link PMC2994686 Disease Relevance 0.40 Pain Relevance 0.03
In some endothelial populations, CysLT1 is much more abundant than CysLT2 and has affinities for LTD4 and LTC4 of approximately 1 nM and 10 nM, respectively.
LTD4 Binding (affinities) of
12) Confidence 0.10 Published 2010 Journal PLoS Biology Section Body Doc Link PMC2994686 Disease Relevance 0.52 Pain Relevance 0.03
CysLTs exert their biological actions by binding to two types of G protein-coupled receptors, i.e., cysteinyl leukotriene receptor 1 (CYSLTR1), which is sensitive to the asthma drugs montelukast (MLK), zafirlukast, and pranlukast,8,9 and CYSLTR2.10
cysteinyl leukotriene receptor 1 Binding (binding) of associated with asthma
13) Confidence 0.09 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2831603 Disease Relevance 1.23 Pain Relevance 0.42
Metaplasticity is often governed by homeostatic mechanisms that help to maintain synaptic strength within a functional range [8] This means that the capacity to undergo LTP or LTD is modulated by the recent history of synaptic activation in a homeostatic fashion introducing a bias towards LTP after prolonged inactivity and towards LTD after persistent activation.
LTD Binding (undergo) of associated with depression and long-term potentiation
14) Confidence 0.05 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.66 Pain Relevance 0.66
HFSLTP-LTD intervention before and after Botulinum Toxin Treatment
HFSLTP-LTD Binding (intervention) of associated with depression
15) Confidence 0.05 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.34 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox